Companies / BOC Sciences / Benralizumab
BOC Sciences

Benralizumab | BOC Sciences

Benralizumab, an interleukin-5 receptor _ (IL-5R_)-directed cytolytic monoclonal antibody, induces direct, rapid and almost complete depletion of eosinophils by enhancing antibody-dependent cell-mediated cytotoxicity. It can be used for severe eosinophilic asthma.

Reviews


No reviews yet

ABOUT THE COMPANY

BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.
  • See More